MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)*
Organization & Developments: Sangamo
Parents
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)*
Children
*Formed a collaboration with the New York-based CHDI Foundation to develop a new treatment for Huntington’s disease.
*Most of Sangamo’s presentations at the gene therapy meeting in Seattle focused on using its technology in a number of other diseases, like HIV, hemophilia, and retinal neurodegeneration
*Proprietary “zinc-finger protein technology,” which is designed to edit specific DNA sequences inside a cell, to, say, turn off a disease activity.
*Results are due from a trial of an experimental drug of this variety in 170 patients with diabetic neuropathy—a big potential application of the technology (2011)
2011: Sangamo Partners With CHDI (2011)
2014: 2014: Biogen Idec forges a $320M gene editing deal aimed at curing inherited blood disorders (2014)
2016: Fresh Blood In Off-The-Shelf CAR-T Marathon
2018: Sangamo in $3 billion gene-editing deal with Gilead
2018: Sangamo Therapeutics: More Catalysts Powering A Gene-Based Innovator
2018: Sangamo Tumbles On MPS II Data, But It Was Grossly Misunderstood_seekingalpha.com
2019: Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals_www.investors.com
2019: Sangamo shares take a big hit as investors react to setback for pioneering gene-editing tech – Endpoints News
2019: Sangamo's Hemophilia A Results Light A Spark And Push Program Into Pfizer's Hands_seekingalpha.com
2020: Sangamo: 'Good Companies Get Bought, Not Sold'
2020: Sangamo: Stalking A Speculative Buy In 2020_seekingalpha.com
2020: Sizing Up Sangamo Therapeutics
2021: Revisting Sangamo Therapeutics
2021: Sangamo: Partnering A Path To The Future Of Medicine
2022: Sangamo Therapeutics (SGMO) Investor Presentation - Slideshow_seekingalpha.com
2022: Sangamo Therapeutics: Lost In Transition From Lab To Clinic_seekingalpha.com
2022: Sangamo Therapeutics: Ready To Dust Off My Dormant Position Ahead Of A Pivotal 2023
2022: Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead_seekingalpha.com
2023: Sangamo lays off 160+ staffers, winds down facility, punts clinical programs in drastic revamp
2023: Spurned by Big Pharma collaborators, Sangamo lays off 27% of US staff in latest refocus_ fiercebiotech
2024: Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
2024: Sangamo slashes time to market for Fabry gene therapy as FDA agrees to accelerated approval package
2024: Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
2024: Sangamo Therapeutics Lands Major $1.3B Gene Therapy Deal with Astellas for Brain Disease Treatment
2024: Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development_seekingalpha.com
2024: Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
2025: Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
2025: Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit
2025: Sangamo Therapeutics: Left At The Alter (Rating Downgrade)
Jumps
*Key People: Sangamo
Finance & Acquisition: Sangamo